Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Real-World Utilization of Immune Globulin Subcutaneous 16.5% in Treatment-Naïve Primary Immunodeficient Patients
Presented at ACAAI 2022 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD Lucinda J. Van Anglen, PharmD View...
Real-World Utilization of Immune Globulin Intravenous 10% at Physician Office Infusion Centers
Presented at ACAAI 2022 Authors: Richard F. Herrscher, MD, FACAAI Quyen Luu, MD Dawn N. Kim-Romo, PharmD, PhD Lucinda J. Van Anglen, PharmD View...
Real-World Ustekinumab Use in Pediatric Patients with Crohn’s Disease
Presented at ACG 2022 Authors: Timothy E. Ritter, MD Harry E. Sarles, MD, FACG Annette E. Whitney, MD Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View Poster View...
Management of Home Parenteral Nutrition in Gastroenterology Office Infusion Centers
Presented at ACG 2022 Authors: Timothy E. Ritter, MD Dawn N. Kim-Romo, PharmD, PhD, MS Claudia P.Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster View...
Real-World Experience with Microbiota Treatment for the Prevention of Recurrent Clostridioides difficile Infection
Presented at ACG 2024 Authors: Timothy E. Ritter, MD Jonathan A. Rosenberg, MD Richard L. Hengel MD Sujatha Krishan, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, PharmD Kelly E. Hanna, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Sanghyuk Seo, PharmD, MS...
A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
Published December 4, 2021 Richard L. Hengel, MD Brian S. Metzger, MD, MPH H. Barry Baker, MD, FACP John S. Adams, MD Ramesh V. Nathan, MD, FIDSA Rishi Bhattacharyya, MD Richard M. Mandel, MD, FIDSA Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder,...
Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings
Presented on October 24, 2016 Robin H. Dretler, MD, FIDSA - Infectious Disease Specialists of Atlanta, PC, Decatur, GA Quyen Luu, MD, Macon, GA Richard C. Prokesch, MD, FACP, FIDSA - Infectious Diseases Associates, Riverdale, GA Andrew H. Krinsky, MD - Infectious...
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)
Presented on October 7, 2015 Barry Statner, MD, CM FRCPC, FIDSA Fernando S. Alvarado, MD, MPH, TM Brian Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD H. Barry Baker, MD, FACP Alfred E. Bacon III, MD Claudia P. Schroeder, PharmD, PhD Lucinda J....
Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC)
Presented on October 8, 2014 Richard C. Prokesch, MD, FACP, FIDSA -Infectious Disease Associates, Riverdale, GA John S. Adams, MD, FIDSA -Knoxville Infectious Disease Consultants, PC, Knoxville, TN Ramesh V. Nathan, MD- Mazur, Statner, Dutta, Nathan, PC, Thousand...
Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization
Presented on October 27, 2009 Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc, Sugar Land, TX Michael P. Dailey, MD - Infectious Disease Services of GA, Roswell, GA Andrew H. Krinsky, MD - Infectious Disease Associates, Sarasota, FL John S. Adams, MD -...
Publication: Outpatient Treatment of Osteomyelitis with Telavancin
Published July 2017 Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Robin H. Dretler, MD John S. Adams, MD, FIDSA, FSHEA Richard C. Prokesch, MD, FACP, FIDSA Quyen Luu, MD Andrew H. Krinsky, MD View...
Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes
Presented on October 24, 2016 Brian S. Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD Barry Statner, MD, FRCPC, FIDSA John S. Adams, MD, FIDSA, FSHEA Alfred E. Bacon, III, MD Kimberly Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder, PharmD,...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.